Richard  Chin net worth and biography

Richard Chin Biography and Net Worth

Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Drugs Richard developed, including Lucentis®, Xolair®, Tysabri®, and Rituxan® for immune diseases, have current aggregate sales of well over $10 billion per year.

Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech where he oversaw all of Genentech’s drug development programs except oncology products; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. Richard was named by BusinessWeek in 2006 as one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.

What is Richard Chin's net worth?

The estimated net worth of Richard Chin is at least $14.56 million as of August 2nd, 2021. Dr. Chin owns 1,574,271 shares of Kindred Biosciences stock worth more than $14,562,007 as of November 25th. This net worth estimate does not reflect any other assets that Dr. Chin may own. Learn More about Richard Chin's net worth.

How do I contact Richard Chin?

The corporate mailing address for Dr. Chin and other Kindred Biosciences executives is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. Kindred Biosciences can also be reached via phone at (650) 701-7901 and via email at [email protected]. Learn More on Richard Chin's contact information.

Has Richard Chin been buying or selling shares of Kindred Biosciences?

Richard Chin has not been actively trading shares of Kindred Biosciences over the course of the past ninety days. Most recently, Richard Chin sold 40,000 shares of the business's stock in a transaction on Monday, August 2nd. The shares were sold at an average price of $9.21, for a transaction totalling $368,400.00. Following the completion of the sale, the chief executive officer now directly owns 1,574,271 shares of the company's stock, valued at $14,499,035.91. Learn More on Richard Chin's trading history.

Richard Chin Insider Trading History at Kindred Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/2/2021Sell40,000$9.21$368,400.001,574,271View SEC Filing Icon  
7/2/2021Sell40,000$9.18$367,200.001,894,271View SEC Filing Icon  
6/16/2021Sell40,000$9.18$367,200.001,934,271View SEC Filing Icon  
1/2/2019Sell40,000$10.57$422,800.001,906,071View SEC Filing Icon  
12/3/2018Sell40,000$13.28$531,200.001,946,071View SEC Filing Icon  
11/1/2018Sell40,000$14.68$587,200.001,986,071View SEC Filing Icon  
10/1/2018Sell40,000$13.28$531,200.002,026,071View SEC Filing Icon  
9/5/2018Sell40,000$14.79$591,600.002,073,671View SEC Filing Icon  
8/1/2018Sell40,000$13.51$540,400.002,106,071View SEC Filing Icon  
7/2/2018Sell40,000$10.28$411,200.002,146,071View SEC Filing Icon  
6/1/2018Sell40,000$10.13$405,200.002,226,071View SEC Filing Icon  
5/30/2018Sell12,610$10.00$126,100.002,226,071View SEC Filing Icon  
5/25/2018Sell3,060$10.00$30,600.002,241,681View SEC Filing Icon  
5/18/2018Sell2,400$10.00$24,000.002,241,741View SEC Filing Icon  
5/9/2018Sell1,930$10.01$19,319.302,244,341View SEC Filing Icon  
5/7/2018Sell1,730$10.01$17,317.302,244,341View SEC Filing Icon  
5/1/2018Sell20,000$9.05$181,000.002,246,071View SEC Filing Icon  
4/2/2018Sell20,000$8.39$167,800.002,266,071View SEC Filing Icon  
7/3/2017Sell13,000$8.26$107,380.002,297,546View SEC Filing Icon  
6/22/2017Sell13,000$7.75$100,750.002,310,546View SEC Filing Icon  
See Full Table

Richard Chin Buying and Selling Activity at Kindred Biosciences

This chart shows Richard Chin's buying and selling at Kindred Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kindred Biosciences Company Overview

Kindred Biosciences logo
Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.
Read More

Today's Range

Now: $9.25
Low: $9.24
High: $9.26

50 Day Range

MA: $9.22
Low: $9.08
High: $9.25

2 Week Range

Now: $9.25
Low: $3.46
High: $9.28

Volume

178,496 shs

Average Volume

840,890 shs

Market Capitalization

$420.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3